Qi Xia

Dr. Qi Xia


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Affective Disorders
Verified
Journal Article
Closed access
LWLi Wei
Li Wei
YDYupeng Du
Yupeng Du
WWWei Wu
Wei Wu
XFXuyan Fu
Xuyan Fu
QXQi Xia
Qi Xia

23 April 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
YWYouhe Wu
Youhe Wu
YJYiheng Jiang
Yiheng Jiang
YGYanrong Gong
Yanrong Gong
TYTing Yao
Ting Yao
QZQi Zheng
Qi Zheng
LLLanjuan Li
Lanjuan Li
Probiotic therapy holds potential for preventing and treating various gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome (IBS-D). Previous studies have suggested that it can help restore intestinal mucosal immunity and gut microbiota dysbiosis in IBS-D patients. Probiotics regulate host microbial metabolism and immune homeostasis, thereby improving host health. Effective and persistent colonization is crucial for probiotic therapy, but oral probiotics often suffer from limited efficacy due to loss of biological activity and insufficient colonization in the complex intestinal environment. Currently, formulations that specifically target gut mucosal colonization are scarce. We developed a "Janus" structured nanoclay microgel via microfluidics encapsulating Pediococcus pentosaceus Li05 (Li05) towards this end. Polydopamine enhanced the microgel's adhesion to the intestinal mucosa, prolonging its residence time in the intestine and enabling targeted delivery of active Li05. The nanoclay promoted Li05 aggregation and growth through charge adsorption, preserving its biological activity and ensuring an effective dose for gut colonization. In vivo studies demonstrated that the nanoclay microgel significantly alleviated diarrhea, mucosal inflammation, and gut microbiota dysbiosis in an IBS-D rat model. These findings suggest that this nanoclay microgel is an effective gut targeted formulation able to promote probiotic growth, offering new approaches for future probiotic therapy in IBS-D.

11 October 2023 in Digestive Diseases
Verified
Journal Article
Open access
PDF file
MSMenghan Su
Menghan Su
TYTing Ye
Ting Ye
WWWei Wu
Wei Wu
ZSZheyue Shu
Zheyue Shu
QXQi Xia
Qi Xia
Background: Chronic hepatitis B (CHB) infection is still a major global public health problem, with nearly two billion patients. Although current antiviral drugs can inhibit viral replication and reduce hepatitis B virus (HBV) related complications, it is difficult to achieve clinical endpoints due to drug resistance. Summary: Immune checkpoint inhibitors (ICIs) are an important strategy to reverse T-cell exhaustion, and rebuilding an effective functional T-cell response is a promising immunomodulatory approach for CHB patients. However, ICIs may lead to viral reactivation or immune-related adverse effects. There are still many controversies in the application of ICIs in treating patients with CHB. Key Messages: This article reviews the research progress of ICIs in CHB infection and related issues. The goal of this paper was to summarize the possible impact of new therapies for CHB with the aim of reducing potential clinical risks.

13 November 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YZYi Zhang
Yi Zhang
WWWei Wu
Wei Wu
YWYijie Wang
Yijie Wang
LTLingjia Tong
Lingjia Tong
MHMeng Hong
Meng Hong
ZCZhi Chen
Zhi Chen
Objectives: Toll-like receptors (TLRs) on neutrophils play a crucial role in detecting pathogens and organ/tissue injury in acute-on-chronic liver failure (ACLF). However, little is known about the exact mechanisms and potential signalling pathways. The aim of this study was to investigate alterations in TLR signalling pathways in neutrophils of ACLF patients. Methods: Twenty-seven patients with compensated cirrhosis (n = 9), decompensated cirrhosis (n = 9) and ACLF (n = 9) were enrolled in the study. Neutrophils were isolated, and alterations in TLR signalling pathways were evaluated using an RT2 Profiler™ PCR Array. The fold change for each gene (2(−∆∆CT)) was compared among the groups. Genes with a fold change ratio of ≥ 2 or ≤ 0.5 along with a p value of < 0.05 were considered to be differentially expressed. Results: A total of 17 genes were upregulated in neutrophils from patients with compensated cirrhosis and were mainly distributed in adaptors, TLR-interacting proteins and downstream pathways. Six genes were detected in patients with decompensated cirrhosis. A trend of downregulation of genes in the TLR signalling pathway was observed in neutrophils of patients with cirrhosis and ACLF. TLR3, IFNG, IL1B, TBK1, CCL2 and LTA were downregulated in neutrophils. Moreover, CD14 and IL10 were upregulated in neutrophils of ACLF patients. Conclusions: TLR signalling pathway genes were differentially regulated in neutrophils between cirrhosis and ACLF. In ACLF patients, defective expression of TLR3 and IFN, along with enhanced CD14 and IL10 expression, was characterized by transcriptional alterations of neutrophils.

3 June 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
YZYi Zhang
Yi Zhang
YWYijie Wang
Yijie Wang
WWWei Wu
Wei Wu
PLPing Liu
Ping Liu
SSShanshan Sun
Shanshan Sun
ZCZhi Chen
Zhi Chen
Background: We aimed to analyze the level of carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) in neutrophils of ischemic stroke (IS) patients at different stages, together with its roles in neutrophils.Patients and methods: Sixty‐seven patients were classified into acute phase group (n = 19), subacute phase group (n = 28), and stable phase group (n = 20), and 20 healthy individuals who had received physical examination at the same time period as healthy control. We then analyzed the expression level of CEACAM1 and cell viability in CEACAM1 positive and CEACAM1 negative neutrophils by flow cytometry and the content of plasma CEACAM1, neutrophil gelatinase‐associated lipocalin (NGAL), matrix metalloproteinases‐9 (MMP‐9) was measured using enzyme‐linked immunosorbent assay (ELISA), while that of interleukin‐10 (IL‐10) and tumor necrosis factor (TNF) was determined using a Human Enhanced Sensitivity Flex set.Results: Compared with healthy control, the percentage of CEACAM1 positive neutrophils in IS patients showed a significant increase, and a significant increase was also noticed in the content of plasma CEACAM1 at the subacute stage. Reduction in cell viability was observed in CEACAM1 positive neutrophils compared with CEACAM1 negative counterparts. There was a positive correlation between CEACAM1 expression rate in neutrophils and plasma CEACAM1 and IL‐10 content in the subacute group. Compared with acute group and healthy control group, there was an instinct increase in the level of plasma MMP‐9 and NGAL in subacute group.Conclusions: Our data showed that there was a rapid increase of CEACAM1 in neutrophils at the acute stage of IS. We speculated that CEACAM1 may serve as an inhibitory regulator involving in the progression of IS.

15 January 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
QXQi Xia
Qi Xia
WDWanrong Dai
Wanrong Dai
KXKaijin Xu
Kaijin Xu
QNQin Ni
Qin Ni
YLYongtao Li
Yongtao Li
LLLanjuan Li
Lanjuan Li